Both high and low HbA1c predict incident heart failure in type 2 diabetes mellitus

Circulation: Heart Failure

Volumn 8, Issue 2, 2015, Pages 236-242

  Parry, Helen M ^a   Deshmukh, Harshal ^a   Levin, Daniel ^a   Van Zuydam, Natalie ^a   Elder, Douglas H J ^a   Morris, Andrew D ^a   Struthers, Allan D ^a   Palmer, Colin N A ^a   Doney, Alex S F ^a   Lang, Chim C ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

diabetes mellitus; echocardiography; glucose

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CREATININE; HEMOGLOBIN A1C; INSULIN; METFORMIN; SULFONYLUREA; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HEART FAILURE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE; BLOOD; DIABETES MELLITUS, TYPE 2; RISK FACTOR;

AGED; COMORBIDITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; HEART FAILURE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS;

EID: 84937570603     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.113.000920     Document Type: Article

References (46)

1. Gottdiener JS, Arnold AM, Aurigemma GP, Polak JF, Tracy RP, Kitzman DW, Gardin JM, Rutledge JE, Boineau RC. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol. 2000;35:1628-1637.
2. Peterson LR, McKenzie CR, Schaffer JE. Diabetic cardiovascular disease: getting to the heart of the matter. J Cardiovasc Transl Res. 2012;5:436-445. doi: 10.1007/s12265-012-9374-7.
3. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation. 2007;115:3213-3223. doi: 10.1161/CIRCULATIONAHA.106.679597.
4. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303-310. doi: 10.1056/NEJM199108013250502.
5. Wold LE, Ceylan-Isik AF, Fang CX, Yang X, Li SY, Sreejayan N, Privratsky JR, Ren J. Metallothionein alleviates cardiac dysfunction in streptozotocin-induced diabetes: role of Ca2+ cycling proteins, NADPH oxidase, poly(ADP-Ribose) polymerase and myosin heavy chain isozyme. Free Radic Biol Med. 2006;40:1419-1429. doi: 10.1016/j. freeradbiomed.2005.12.009.
6. Ritchie RH, Quinn JM, Cao AH, Drummond GR, Kaye DM, Favaloro JM, Proietto J, Delbridge LM. The antioxidant tempol inhibits cardiac hypertrophy in the insulin-resistant GLUT4-deficient mouse in vivo. J Mol Cell Cardiol. 2007;42:1119-1128. doi: 10.1016/j.yjmcc.2007.03.900.
7. Miki T, Yuda S, Kouzu H, Miura T. Diabetic cardiomyopathy: pathophysiology and clinical features. Heart Fail Rev. 2013;18:149-166. doi: 10.1007/s10741-012-9313-3.
8. Zhou YT, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, Orci L, Unger RH. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci USA. 2000;97:1784-1789.
9. Trost SU, Belke DD, Bluhm WF, Meyer M, Swanson E, Dillmann WH. Overexpression of the sarcoplasmic reticulum Ca(2+)-ATPase improves myocardial contractility in diabetic cardiomyopathy. Diabetes. 2002;51:1166-1171.
10. Iribarren C, Karter AJ, Go AS, Ferrara A, Liu JY, Sidney S, Selby JV. Glycemic control and heart failure among adult patients with diabetes. Circulation. 2001;103:2668-2673.
11. Lind M, Olsson M, Rosengren A, Svensson AM, Bounias I, Gudbjörnsdottir S. The relationship between glycaemic control and heart failure in 83, 021 patients with type 2 diabetes. Diabetologia. 2012;55:2946-2953. doi: 10.1007/s00125-012-2681-3.
12. Nichols GA, Joshua-Gotlib S, Parasuraman S. Independent contribution of A1C, systolic blood pressure, and LDL cholesterol control to risk of cardiovascular disease hospitalizations in type 2 diabetes: an observational cohort study. J Gen Intern Med. 2013;28:691-697. doi: 10.1007/s11606-012-2320-1.
13. Pazin-Filho A, Kottgen A, Bertoni AG, Russell SD, Selvin E, Rosamond WD, Coresh J. HbA 1c as a risk factor for heart failure in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Diabetologia. 2008;51:2197-2204. doi: 10.1007/s00125-008-1164-z.
14. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-2572.
15. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129-139. doi: 10.1056/NEJMoa0808431.
16. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-2559.
17. Castagno D, Baird-Gunning J, Jhund PS, Biondi-Zoccai G, MacDonald MR, Petrie MC, Gaita F, McMurray JJ. Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37, 229 patient meta-analysis. Am Heart J. 2011;162:938-948.e2. doi: 10.1016/j.ahj.2011.07.030.
18. Wadén J, Forsblom C, Thorn LM, Gordin D, Saraheimo M, Groop PH; Finnish Diabetic Nephropathy Study Group. A1C variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes. Diabetes. 2009;58:2649-2655. doi: 10.2337/db09-0693.
19. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 1998;316:823-828.
20. Morris AD, Boyle DI, MacAlpine R, Emslie-Smith A, Jung RT, Newton RW, MacDonald TM. The diabetes audit and research in Tayside Scotland (DARTS) study: electronic record linkage to create a diabetes register. BMJ. 1997;315:524-528.
21. Doney ASF, Fischer B, Leese G, Morris AD, Palmer CNA. Cardiovascular risk in type 2 diabetes is associated with variation at the PPARG locus. Arterioscler Thromb Vasc Biol. 2004;24:2403-2407. doi: 10.1161/01. ATV.0000147897.57527.e4.
22. Zhou K, Bellenguez C, Spencer CC, Bennett AJ, Coleman RL, Tavendale R, Hawley SA, Donnelly LA, Schofield C, Groves CJ, Burch L, Carr F, Strange A, Freeman C, Blackwell JM, Bramon E, Brown MA, Casas JP, Corvin A, Craddock N, Deloukas P, Dronov S, Duncanson A, Edkins S, Gray E, Hunt S, Jankowski J, Langford C, Markus HS, Mathew CG, Plomin R, Rautanen A, Sawcer SJ, Samani NJ, Trembath R, Viswanathan AC, Wood NW, Harries LW, Hattersley AT, Doney AS, Colhoun H, Morris AD, Sutherland C, Hardie DG, Peltonen L, McCarthy MI, Holman RR, Palmer CN, Donnelly P, Pearson ER. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet. 2011;43:117-120. doi: 10.1038/ng.735.
23. Elder DHJ, Donnelly L, Wong A 011 HbA1c and mortality in diabetic individuals with heart failure: an observational cohort study. Heart. 2012;98:A9-A10.
24. Doney AS, Lee S, Leese GP, Morris AD, Palmer CN. Increased cardiovascular morbidity and mortality in type 2 diabetes is associated with the glutathione S transferase theta-null genotype: a Go-DARTS study. Circulation. 2005;111:2927-2934. doi: 10.1161/CIRCULATIONAHA.104.509224.
25. Nadir MA, Wei L, Elder DH, Libianto R, Lim TK, Pauriah M, Pringle SD, Doney AD, Choy AM, Struthers AD, Lang CC. Impact of reninangiotensin system blockade therapy on outcome in aortic stenosis. J Am Coll Cardiol. 2011;58:570-576. doi: 10.1016/j.jacc.2011.01.063.
26. Elder DH, Wei L, Szwejkowski BR, Libianto R, Nadir A, Pauriah M, Rekhraj S, Lim TK, George J, Doney A, Pringle SD, Choy AM, Struthers AD, Lang CC. The impact of renin-angiotensin-aldosterone system blockade on heart failure outcomes and mortality in patients identified to have aortic regurgitation: a large population cohort study. J Am Coll Cardiol. 2011;58:2084-2091. doi: 10.1016/j.jacc.2011.07.043.
27. Struthers A, Shearer F. Allopurinol: novel indications in cardiovascular disease. Heart. 2012;98:1543-1545. doi: 10.1136/heartjnl-2012-302249.
28. Szwejkowski BR, Elder DH, Shearer F, Jack D, Choy AM, Pringle SD, Struthers AD, George J, Lang CC. Pulmonary hypertension predicts all-cause mortality in patients with heart failure: a retrospective cohort study. Eur J Heart Fail. 2012;14:162-167. doi: 10.1093/eurjhf/hfr159.
29. Penno G, Solini A, Bonora E, Fondelli C, Orsi E, Zerbini G, Morano S, Cavalot F, Lamacchia O, Laviola L, Nicolucci A, Pugliese G; Renal Insufficiency And Cardiovascular Events Study Group. HbA1c variability as an independent correlate of nephropathy, but not retinopathy, in patients with type 2 diabetes: the Renal Insufficiency and Cardiovascular Events (RIACE) Italian multicenter study. Diabetes Care. 2013;36:2301-1. doi: 10.2337/dc12-2264.
30. Ihaka R, Gentleman R. R: a language for data analysis and graphics. J Comput Graphical Stat. 1996;5:299-314. doi 10.1080/10618600.1996.10474713.
31. Currie CJ, Peters JR, Tynan A, Evans M, Heine RJ, Bracco OL, Zagar T, Poole CD. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet. 2010;375:481-489. doi: 10.1016/S0140-6736(09)61969-3.
32. Database GPR. General Practice Research Database. 2009.
33. Stewart S, MacIntyre K, Capewell S, McMurray JJ. Heart failure and the aging population: an increasing burden in the 21st century? Heart. 2003;89:49-53.
34. Lind M, Odén A, Fahlén M, Eliasson B. The true value of HbA1c as a predictor of diabetic complications: simulations of HbA1c variables. PLoS One. 2009;4:e4412. doi: 10.1371/journal.pone.0004412.
35. McGuire DK, See R, Abdullah SM, Snell PG, McGavock JM, Ayers CR, Szczepaniak LS. The effect of rosiglitazone on integrated cardiovascular performance, cardiac structure, function and myocardial triglyceride: trial design and rationale. Diab Vasc Dis Res. 2009;6:43-50. doi: 10.3132/dvdr.2009.009.
36. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-853.
37. Maru S, Koch GG, Stender M, Clark D, Gibowski L, Petri H, White AD, Simpson RJ Jr. Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting. Diabetes Care. 2005;28:20-26.
38. McAlister FA, Eurich DT, Majumdar SR, Johnson JA. The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy. Eur J Heart Fail. 2008;10:703-708. doi: 10.1016/j. ejheart.2008.05.013.
39. Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, Hughes RI, Khunti K, Wilkins MR, Majeed A, Elliott P. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ. 2009;339:b4731.
40. Frier BM, Schernthaner G, Heller SR. Hypoglycemia and cardiovascular risks. Diabetes Care. 2011;34 Suppl 2:S132-S137. doi: 10.2337/dc11-s220.
41. Kilpatrick ES, Rigby AS, Atkin SL. A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care. 2008;31:2198-2202. doi: 10.2337/dc08-0864.
42. Hsu CC, Chang HY, Huang MC, Hwang SJ, Yang YC, Lee YS, Shin SJ, Tai TY. HbA1c variability is associated with microalbuminuria development in type 2 diabetes: a 7-year prospective cohort study. Diabetologia. 2012;55:3163-3172. doi: 10.1007/s00125-012-2700-4.
43. Li W, Liu X, Yanoff M, Cohen S, Ye X. Cultured retinal capillary pericytes die by apoptosis after an abrupt fluctuation from high to low glucose levels: a comparative study with retinal capillary endothelial cells. Diabetologia. 1996;39:537-547.
44. Quagliaro L, Piconi L, Assaloni R, Martinelli L, Motz E, Ceriello A. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes. 2003;52:2795-2804.
45. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295:1681-1687. doi: 10.1001/jama.295.14.1681.
46. Tsutsui H, Kinugawa S, Matsushima S. Oxidative stress and heart failure. Am J Physiol Heart Circ Physiol. 2011;301:H2181-H2190. doi: 10.1152/ajpheart.00554.2011.